Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Magnetic Resonance Imaging and Spectroscopy of the Prostate

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 26, 2007
Last updated: February 27, 2013
Last verified: February 2013
Past studies have shown that MRI is useful for staging prostate cancer. This study will use magnetic resonance spectroscopic imaging (MRSI) to obtain more information. MRSIs with MRIs help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. This study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.

Condition Intervention
Prostate Cancer
Other: MRI and MRSI

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Magnetic Resonance Imaging and Spectroscopy of the Prostate

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Determine added value in combining MRSI and MRI in prostate cancer treatment [ Time Frame: 3 hours ]

Enrollment: 1005
Study Start Date: December 2000
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 - MRSI / MRI Other: MRI and MRSI
Compare treatment impact when using MRI and MRSI


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Urology and Radiology prostate cancer patients seen at Memorial Sloan-Kettering Cancer Center

Inclusion Criteria:

  • prostate cancer patients willing to undergo a MRI and MRSI exam

Exclusion Criteria:

  • patients with prostate cancer and bone or lymph node metastasis
  • patients who can not have an MRI exam
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00590993

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Hedvig Hricak, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00590993     History of Changes
Other Study ID Numbers: 00-136
Study First Received: December 26, 2007
Last Updated: February 27, 2013

Keywords provided by Memorial Sloan Kettering Cancer Center:
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on May 25, 2017